Immunocan

Today we Immunocan are thrilled to announce that we have joined Bayer Co.Lab in China as a resident company, harnessing Bayer’s extensive innovation and collaboration network to access worldwide resources and expertise, for accelerating global expansion of Immunocan’s gene-edited animal-based antibody discovery platform. For more information, please visit www.immunocan.com.

?? Immunocan Joins Bayer Co.Lab in China ?? ?? Shanghai, China, December 10, 2024 – Shanghai Immunocan Biotech Co., Ltd. (Immunocan)?today announced that it has entered into agreement with Bayer. Immunocan will join Bayer Co.Lab (Bayer Co.Lab) in China as a resident company, harnessing Bayer’s extensive innovation and collaboration network to access worldwide resources and expertise, for accelerating global expansion of Immunocan’s gene-edited animal-based antibody discovery platform. ?? ??About Immunocan Immunocan was founded in 2020 and specializes in using gene editing technology to replace immunoglobulin variable region genes in various animals, resulting in genetically engineered animals capable of producing fully human antibodies and other innovative modalities. The company is committed to offering cutting-edge antibody discovery platforms to worldwide drug research partners, with the goal of developing safer and more effective treatments for human diseases. ??About Bayer Co.Lab Bayer Co.Lab inaugurated its new site in China this September as part of its global network of life sciences incubators. Bayer Co.Lab not only provides resident companies the state-of-the-art infrastructure and lab space but also grants access to Bayer’s global R&D network and expertise, helping biotech startups connect with resources in the global pharmaceutical industry. In China, Bayer Co.Lab aims to empower local biotech startups with a focus on cutting-edge innovations in the areas of CGT, oncology and new technology platforms. Following the inauguration of its new site in Berlin this November, Bayer Co.Lab has expanded to global innovation hubs, including United States, Japan, China, and Germany, dedicated to supporting local startups in accelerating their innovations. ??About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Immunocan wishes you and your family a Happy Mid-Autumn Festival!

Only 1 Week Left Until the World Bispecific Summit! Join us Immunocan and connect with Pauli Wang, MBA to discuss our new common-light-chain bispecific antibody platform with higher performance and expandable potential. Let's explore how ImmuMab Light? mouse can help accelerate your bispecific antibody discovery.

WE ARE IN! We Immunocan are excited to be participating in the 15th World Bispecific Summit 2024 in Boston, September 3-5. We can't wait to connect with you and collaborate on accelerating bi/multi-specific antibody discovery. Let’s make a difference together! #bispecific

Immunocan will be attending 2024 Immuno-Oncology Summit this week. If you're attending, our Business Development, Pauli Wang, MBA, looks forward to discussing the latest developments in immunotherapies with you.

Immunocan is one of the leading companies operating in global gene editing market. Immunocan's core technology MASIRT? features one-step gene replacement at Mb scale between two species. Its advantageous genome-engineering efficiency enables rapid construction of multiple specialized antibody discovery platforms, including mice generating fully human antibodies or alpaca antibodies and rabbits generating fully human antibodies.

WE ARE IN! We Immunocan are thrilled to be participating in Immuno-Oncology Summit 2024 in Philadelphia, August 7-9. We look forward to seeing you there and making a difference. Together, let's accelerate antibody discovery! #IOSummit

Since the first mouse-derived monoclonal antibody drug OKT3 (muromonab-CD3) was marketed in 1986, over 120 antibody drugs from different sources have been approved by FDA and brought clinical benefits to patients. Despite flexibility and well-established application process, ritual use of mice during antibody generation brought limitations for drug development space. Due to the low utilization of Immunoglobulin Lambda genes in wildtype mice (about 5%, varying by strain), antibodies with Lambda light chain (λ-antibodies) have always been under-scrutinized. As of December 31, 2023, only 14 FDA-approved antibody drugs contain Lambda light chain, and most of these are from transgenic mice or human antibody library used in display technologies. In humans, naturally occurring λ-antibodies are approximately 35% of the antibody repertoire and plays important role in adaptive immunity. Different individuals generate immune repertoires with different preferences of light chain type in response to different immunogens. Within the immune repertoire against the same antigen, λ-antibodies can target different epitopes from κ-antibodies. Therefore, using an antibody generation model containing human Lambda light chains can significantly enhance the epitope coverage of the immune repertoire and increase the success rate of obtaining candidate antibodies fitting target product profile. By proprietary Massive-fragment Across Species In-situ Replacement Technology (MASIRT?), Immunocan achieved humanization of Lambda light chain variable regions of ImmuMab? mouse, which increased the total humanized immunoglobulin variable region to 3.2 Mb. This innovation provides the industry with source of λ-antibody repertoires of higher diversity and developability compared to existing platforms. Immunocan's multi-species antibody generation strategy not only expands the potential for antibody discovery and development but also provides more therapeutic options for treating complex diseases. Immunocan is looking forward to introducing its innovative antibody discovery platforms to global research partners and seek collaboration to bring safer and more effective therapeutic products to patients worldwide.

NEWS RELEASE! Immunocan Launches New Mouse Strain of Fully Human Antibody Platform: ImmuMab? HKL Mouse, increasing Possibility of Success by Expanded Antibody Repertoires with Lambda Light Chain. Immunocan announced the successful construction of new strain of fully human antibody platform: ImmuMab? HKL mouse. This new mouse was created by in-situ replacing the variable region of Immunoglobulin genes of mouse by its counterparts from human. With Lambda light chain genes humanized, ImmuMab? HKL mouse now contains approximately 3.2 Mb of human immunoglobulin variable region genes, making it the humanized mouse with the longest human immunoglobulin variable regions in the world. By proprietary Massive-fragment Across Species In-situ Replacement Technology (MASIRT?), Immunocan achieved humanization of Lambda light chain variable regions of ImmuMab? mouse, which increased the total humanized immunoglobulin variable region to 3.2 Mb. This innovation provides the industry with source of λ-antibody repertoires of higher diversity and developability compared to existing platforms. For most antigens, especially in the early stage of discovery programs, the light chain preference of preferred lead antibodies is unpredictable. Using mouse generating a significant quantity of human λ-antibodies can prevent the early exclusion of superior lead molecules during antibody generation, increasing the probability of drug development success. In addition to ImmuMab? HKL mouse, Immunocan has already constructed platforms including ImmuMab? HK mouse generating fully human antibody (κ-antibodies), ImmuMab Heavy? mouse generating fully human heavy-chain-only antibody (HCAb), ImmuAlpaca? mouse generating alpaca-derived antibody, and ImmuMab Light? mouse generating fully human common-light-chain antibody. ImmuHeavy? Rabbit is currently under construction to generate rabbit heavy-chain-only antibodies. By continuously innovating in-vivo antibody discovery platforms, Immunocan aims to help partners accelerate the development of novel therapeutics. Immunocan's multi-species antibody generation strategy not only expands the potential for antibody discovery and development but also provides more therapeutic options for treating complex diseases. Immunocan is looking forward to introducing its innovative antibody discovery platforms to global research partners and seek collaboration to bring safer and more effective therapeutic products to patients worldwide. For more information, please visit: https://immunocan.com/ For business cooperation, please contact: [email protected]